Recent Updates
Recently added Catalysts

Soft-tissue Sarcoma: two biotech companies racing to a treatment

OncologyConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$4.0Buniverse median $1.20B
Allocated capital$1.5B$7.9B competing
Phase 3 or filed00 mid, 2 early
Pure plays0this indication only
Capital rank120/299crowding rank 88

Soft-tissue Sarcoma is a two-horse race: Telix Pharmaceuticals (TLX, $4.0B) against Iovance Biotherapeutics (IOVA, $3.9B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $1.5B of allocated capital sits on the pair.

TLX carries 50% of the $7.9B competing here, so the pair is far from evenly matched.

$1.5B of allocated capital sits in Soft-tissue Sarcoma, ranking it 120th of 299 indications by the money committed to it.

Companies developing drugs for Soft-tissue Sarcoma 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TLXTelix Pharmaceuticals89Zr-DFOsq-olaratumabPhase 11$4.0BNo5 11 Sep 2026
IOVAIovance BiotherapeuticsLN-145/LN-144Phase 11$3.9BNo6 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. TLX holds 50% of the $7.9B competing in this indication.

Why Soft-tissue Sarcoma is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Soft-tissue Sarcoma has 2 competitors and a median of $4.0B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Urothelial Cancer1 company · $1.4B · median $1.4BUncontestedIntrahepatic Cholangiocarcinoma1 company · $1.5B · median $6.1BUncontestedGastrointestinal Cancer1 company · $1.5B · median $6.1BUncontestedSystemic Mastocytosis1 company · $1.5B · median $6.1BUncontestedDesmoid Tumor1 company · $1.5B · median $3.1BUncontestedMetastatic Small Cell Lung Cancer1 company · $1.3B · median $4.0BUncontestedAdvanced Renal Cell Carcinoma1 company · $1.3B · median $14.7BUncontestedCastrate-resistant Prostate Cancer1 company · $1.3B · median $14.7BUncontested

Soft-tissue Sarcoma pipeline questions

Which biotech companies are developing drugs for Soft-tissue Sarcoma?

Telix Pharmaceuticals (TLX, 89Zr-DFOsq-olaratumab, Phase 1); Iovance Biotherapeutics (IOVA, LN-145/LN-144, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Soft-tissue Sarcoma.

How advanced is the Soft-tissue Sarcoma pipeline?

Of the 2 clinical-stage programmes in Soft-tissue Sarcoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 2 are in early-stage development.

Which company leads the Soft-tissue Sarcoma field?

TLX is the largest developer in Soft-tissue Sarcoma, holding 50% of the $7.9B of market capitalisation competing in the indication. The median competitor is worth $4.0B.

When is the next Soft-tissue Sarcoma catalyst?

The next dated catalyst in Soft-tissue Sarcoma is TLX on 11 Sep 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map